Adeela Cheema, MD
Geriatric Medicine · Chicago, ILNPI 1841680287
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Novo Nordisk at 24.4% of the total. Among geriatric medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$489
- Lilly USA, LLC$402
- Amgen$283
- Novartis$254
- Pfizer$231
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,07499%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $1,254 |
| AbbVie | 21 | $489 |
| Lilly USA, LLC | 19 | $402 |
| Amgen | 13 | $283 |
| Novartis | 11 | $254 |
| Pfizer | 10 | $231 |
| Otsuka America Pharmaceutical, Inc. | 10 | $222 |
| Exact Sciences | 7 | $176 |
| GSK | 8 | $155 |
| Sumitomo Pharma America, Inc. | 7 | $149 |
| Lundbeck LLC | 8 | $145 |
| Biogen | 6 | $134 |
| Dexcom, Inc. | 4 | $127 |
| Merck | 6 | $120 |
| Boehringer Ingelheim | 6 | $116 |
| AstraZeneca | 4 | $99 |
| Gilead | 4 | $92 |
| Viiv Healthcare Company | 4 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 2 | $56 |
| Sunovion Pharmaceuticals Inc. | 4 | $55 |
| Sanofi Pasteur Inc. | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Bayer | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $36 |
| Cranial Technologies, Inc | 2 | $31 |
| Agios Pharmaceuticals, Inc. | 1 | $30 |
| Dynavax Technologies Corporation | 2 | $29 |
| C2n Diagnostics, LLC | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Genentech USA, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Boston Scientific | 1 | $15 |
How this compares
$5,140 in reported general payments places this provider in the 95th percentile of 147 geriatric medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 94 | $113,318 |
| JanuviaSitagliptin Phosphate | 53 | $75,210 |
| OzempicSemaglutide | 49 | $59,517 |
| MyrbetriqMirabegron | 57 | $46,394 |
| FarxigaDapagliflozin Propanediol | 42 | $34,225 |
| JardianceEmpagliflozin | 16 | $28,087 |
| RybelsusSemaglutide | 13 | $26,687 |
| GemtesaVibegron | 26 | $25,639 |
| MounjaroTirzepatide | 14 | $19,636 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,647 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $14,787 |
| Spiriva HandihalerTiotropium Bromide | 14 | $9,710 |
| Rosuvastatin Calcium | 357 | $6,972 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $6,821 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $5,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $231 | $113,31894 claims |
| Novo NordiskOzempic, Rybelsus | $1,254 | $86,20462 claims |
| MerckJanuvia | $120 | $75,21053 claims |
| AstraZenecaFarxiga | $99 | $34,22542 claims |
| Boehringer IngelheimJardiance | $116 | $28,08716 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $149 | $25,63926 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $155 | $21,19737 claims |
| Lilly USA, LLCMounjaro | $402 | $19,63614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 147 geriatric medicine providers in Illinois.
Other geriatric medicine in Chicago
- Carlos Mella-PicelChicago$9K
- Snigdha KolaChicago$3K
- Annie JohnChicago$2K
- Raj ShahChicago$2K
- Abbas RizviChicago$1K
- Theresa RoweChicago$1K
- Varisha SinghChicago$709
- Gretel Ruiz JorgeChicago$643
- Martin GorbienChicago$640
- Wayne WilliamsonChicago$475
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.